REGIMMUNE-LIMITED
7.11.2022 08:55:38 CET | Business Wire | Press release
REGiMMUNE Limited, a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies for immune disorders and cancer, today announced that the Phase 2b clinical data from 49 patients receiving RGI-2001 for the prevention of acute graft-versus-host disease (aGVHD) will be presented at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana on December 12, 2022.
This is an open label, single-arm Phase 2 study, evaluating the safety and efficacy of RGI-2001 for the prevention of aGVHD in subjects following allogeneic hematopoietic stem cell transplantation (HSCT). This study tests the hypothesis that RGI-2001 prevents GVHD by expanding regulatory T cells soon after allogeneic HSCT. The incidence and severity of aGVHD was evaluated in patients treated with RGI-2001 in addition to standard GVHD prevention medications. “Based on the analysis, RGI-2001 showed reduced incidence of aGVHD with an excellent safety profile. I am thrilled that the RGI-2001 study results have been selected for oral presentation at the ASH meeting. We look forward to sharing future findings as we work to deliver breakthrough immune medicines by harnessing the power of regulatory T cells,” said Kenzo Kosuda, CEO at REGiMMUNE Limited.
Session Name: Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Novel Therapies for Graft-versus-Host Disease
Session Date and Time: Monday, December 12, 2022, 10:30 - 12:00 p.m. CT
Presentation time: 11:45 a.m. CT
Location: Ernest N. Morial Convention Center, 252-254 and online
Presenter: Yi-Bin Chen, MD
Publication Number: 774
Title: RGI-2001 Infusion for Prevention of Acute GVHD after Allogeneic Hematopoietic Cell Transplantation
Submission ID: 162512
About RGI-2001
RGI-2001 is a liposomal formulation of an alpha-galactosylceramide (alpha-GalCer) analog. Alpha-GalCer is a ligand for CD1d expressed on antigen presenting cells and invariant natural killer T cells (iNKT). Liposomal alpha-GalCer promotes tolerogenic immune cascades, resulting in the activation and expansion of regulatory T cells (Tregs). RGI-2001 is REGiMMUNE’s lead drug candidate currently in Phase 3 planning for the prophylaxis of acute graft-versus-host disease (aGVHD).
About REGiMMUNE Limited
REGiMMUNE is a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies by harnessing the power of regulatory T cells (Tregs). REGiMMUNE is creating a pipeline of novel product candidates that either enhance Treg activities for immune diseases or suppress Treg activities for cancer.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221106005119/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ATLAS Infrastructure Cornerstones United Utilities £800m Equity Placement5.5.2026 13:12:00 CEST | Press release
ATLAS participated as an exclusive Cornerstone investor in United Utilities’ equity placement, expanding its existing investment to establish a significant minority shareholding.ATLAS was pleased with the strong support for the transaction from other long-term shareholders signalling broad support for United Utilities’ investment and growth strategy.United Utilities’ fully funded capital investment program underpins a strong multi-year growth trajectory1. ATLAS Infrastructure (“ATLAS”) is a specialist Global Listed Infrastructure investor managing capital on behalf of its funds and long-term institutional clients. ATLAS has been an investor in UU since 2019 and, following the recent equity placement, ATLAS’s actively managed accounts hold a ~6.6% voting and economic interest in United Utilities plc (“UU”). ATLAS recognises the positive new direction established for the UK water sector and welcomes the opportunity to support UU management’s investment plan which will deliver the critica
Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent5.5.2026 12:37:00 CEST | Press release
Highly experienced partners bringing 25+ years of leadership across top-tier life-sciences investment fund, pharma and Biopharma companies, driving accelerated portfolio developmentWith leadership experienceat Blackstone Life Sciences (Deputy Chief Operating Officer), Biogen, (NASDAQ: BIIB), and public and private Biopharma companies (including Kymera Therapeutics (NASDAQ: KYMR)and Cygnal Therapeutics), Elaine Caughey will support portfolio companies in strengthening operational execution, defining robust market access pathways, and enhancing their strategic value through business development support, including partnerships and acquisition transactions. She will also draw on her knowledge of the investment ecosystem to strengthen relationships with investors for both Jeito funds and its portfolio companiesSarah brings deep strategic expertise from senior roles at leading Biopharma investment firms - including as Partner, Marketing and Talent at Abingworth and as Chief Talent Officer at
Datang Mobile, KPN, NEC and Wilus are Latest Licensors to Join Sisvel POS Patent Pool as Incentive Deadline Nears5.5.2026 10:02:00 CEST | Press release
Datang Mobile, KPN, NEC and Wilus have become the latest licensors in the Sisvel point of sale (POS) patent pool. They join seven other patent owners in making their 2G-5G cellular portfolios available through the programme: BlackBerry, Huawei, JVCKENWOOD, LG Electronics, Nokia, Sisvel and SK Telecom. The period for Sisvel POS licensors to benefit from early participation incentives is set to close on 15 May. Cellular patent owners interested in becoming involved should contact Sisvel as soon as possible. The pool, which is the first in the market to address the POS vertical, was announced at the beginning of April, with Huawei, LG Electronics and Nokia as founding licensors. “We have received a great response from the market so far, and I am pleased to welcome Datang, KPN, NEC and Wilus as the latest licensors,” says POS programme manager Sven Törringer. “We have put together a formidable group of cellular technology innovators, and there are many more companies in the pipeline. I am
Bregal Milestone Announces Majority Growth Investment in meteoviva, an AI-Powered Building Energy Management Solution5.5.2026 10:01:00 CEST | Press release
Partnership to scale one of Europe's largest autonomous energy management solutions amid accelerating decarbonisation mandates and rising AI adoption in commercial real estate Bregal Milestone, a leading European software growth private equity firm, today announced a majority growth investment in meteoviva GmbH (“meteoviva” or the “Company”), a pioneer in AI-powered predictive building energy management. meteoviva's intelligent solutions combine a proprietary physics-based thermodynamic model with AI to deliver energy cost reductions of up to 45 percent across large-scale commercial real estate portfolios, without structural retrofits. meteoviva is widely recognised as a market leader in autonomous building energy management, with over 500 buildings across 19 countries, accounting for 11.5 million square metres of real estate under active control. Its customer base includes some of Europe's most demanding buildings, among them Germany's largest office building, The Squaire at Frankfurt
Schindler Selects Navan to Elevate Global Travel Operations5.5.2026 10:00:00 CEST | Press release
Leading provider of sustainable and smart urban mobility deploys Navan to deliver a seamless experience for its workforce Navan (NASDAQ: NAVN), the global AI-powered business travel and expense management platform, today announced it has been selected by Schindler, the leading provider of sustainable and smart urban mobility, to modernize its global travel program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505725595/en/ Leading provider of sustainable and smart urban mobility deploys Navan to deliver a seamless experience for its workforce With over 150 years of industry innovation, Schindler has reshaped mobility in urban societies, growing from a local manufacturer into a global elevator, escalators and moving walkways business. To support its next phase of growth, the company has chosen to consolidate its travel operations – moving away from a fragmented online booking model. By deploying Navan, Schindler is now u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom